



Aravax receives \$1.9 million investment tranche from the Medical Research Commercialisation Fund to complete Phase 1 and prepare for Phase 2.

2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of \$1.9M from the Australian Medical Research Commercialisation Fund (MRCF) to complete the ongoing Phase 1 clinical trial, AVX001, and progress Phase 2 plans for its novel treatment of peanut allergy, PVX108.

These funds were released following Aravax's achievement of research and development milestones to date, which related to progress in pharmaceutical and clinical development activities for PVX108.

We previously reported that in the single ascending dose stage of clinical trial AVX001, there were no adverse events of clinical concern, and no relationship between dose and frequency or severity of adverse events. The trial is now in its second stage which will evaluate the safety and tolerability of repeat administrations of PVX108.

Pascal Hickey, CEO of Aravax said "this additional investment recognises the tremendous progress made by our management and research teams on the development of PVX108 towards a very important cause. We are now working hard on plans for Phase 2 clinical trials of PVX108 which will aim to identify an effective treatment regimen for sufferers of peanut allergy who currently have no therapeutic options available to them."

This \$1.9 million investment tranche will be utilised for the completion of Aravax's Phase 1 study (AVX001) and Phase 2 preparations.

Ends

Media enquiries:

Aravax & MRCF: Andrew Hamilton +61420 447 669 or ah@manacommunications.com

About the Clinical Trial AVX-001

The study is being run at two trial centers: CMAX (Adelaide) phone 1800 150 433, and Nucleus Network (Melbourne) phone 03 8593 9875.

About Aravax

Aravax Pty Ltd

Level 9, 31 Queen Street, Melbourne VIC 3000 Australia
Office +61 3 9657 0700 | Fax +61 3 9657 0777



Aravax is a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The treatment uses highly targeted technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment.

Aravax's technology is underpinned by over a decade of research led by Professor Robyn O'Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council of Australia.

The novel technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. These fragments do not contain the parts of the nut proteins that cause the life-threatening anaphylactic reactions. Aravax's PVX108 therefore has the potential to break the paradigm of allergen immunotherapy by targeting the underlying cause of disease without exposing patients to the risk of acute reactions to treatment.

Aravax is headquartered in Melbourne, Australia.

For more information visit: www.aravax.com.au

About the Australian Medical Research Commercialisation Fund (MRCF)

The MRCF collaboration is managed by the venture capital firm Brandon Capital Partners, and provides seed and venture capital investment to support the development and growth of Australian life science companies.

Established in late 2007, the MRCF is a unique collaboration between major Australian superannuation funds, over 50 leading medical research institutes and research hospitals in Australia and New Zealand. The MRCF supports the development and commercialisation of very early-stage biomedical discoveries originating from these member research organisations, providing both capital and expertise to guide the successful development of new therapies. The MRCF acknowledges the support of the Australian and New Zealand governments, as well as the state governments of Victoria, New South Wales, Western Australia, Queensland, South Australia and the Australian Capital Territory.

For more information visit: www.mrcf.com.au

Aravax Pty Ltd

Level 9, 31 Queen Street, Melbourne VIC 3000 Australia
Office +61 3 9657 0700 | Fax +61 3 9657 0777